Share-based Payment Arrangement, Expense of Avalo Therapeutics, Inc. from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Avalo Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Avalo Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,153,000, a 71% increase year-over-year.
  • Avalo Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,016,000, a 223% increase year-over-year.
  • Avalo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,852,000, a 68% increase from 2023.
  • Avalo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,475,000, a 54% decline from 2022.
  • Avalo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,554,000, a 7.6% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Avalo Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,016,000 $3,153,000 +$1,305,000 +71% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $10,711,000 $2,718,000 +$2,247,000 +477% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $8,464,000 $3,241,000 +$2,612,000 +415% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $5,852,000 $2,904,000 +$2,130,000 +275% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $3,722,000 $1,848,000 +$895,000 +94% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $2,827,000 $471,000 -$422,000 -47% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $3,249,000 $629,000 -$226,000 -26% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $3,475,000 $774,000 -$68,000 -8.1% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $3,543,000 $953,000 +$222,000 +30% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $3,321,000 $893,000 +$224,000 +33% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $3,097,000 $855,000 -$4,457,000 -84% 01 Jan 2023 31 Mar 2023 10-Q/A 11 Jul 2024 2024 Q1
Q4 2022 $7,554,000 $842,000 -$1,050,000 -55% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $8,604,000 $731,000 -$1,027,000 -58% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $9,631,000 $669,000 -$2,405,000 -78% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $12,036,000 $5,312,000 +$3,864,000 +267% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $8,172,000 $1,892,000 +$457,000 +32% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $7,715,000 $1,758,000 +$310,000 +21% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $7,405,000 $3,074,000 +$288,000 +10% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $7,117,000 $1,448,000 +$331,000 +30% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $6,786,000 $1,435,000 +$914,399 +176% 01 Oct 2020 31 Dec 2020 10-K 02 Mar 2022 2021 FY
Q3 2020 $5,871,601 $1,448,000 +$629,207 +77% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $5,242,394 $2,786,000 +$2,259,291 +429% 01 Apr 2020 30 Jun 2020 10-Q 02 Aug 2021 2021 Q2
Q1 2020 $2,983,103 $1,117,000 +$520,307 +87% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $2,462,796 $520,601 -$114,074 -18% 01 Oct 2019 31 Dec 2019 10-K 08 Mar 2021 2020 FY
Q3 2019 $2,576,870 $818,793 -$126,340 -13% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $2,703,210 $526,709 -$81,722 -13% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $2,784,932 $596,693 +$353,869 +146% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,431,063 $634,675 +$329,632 +108% 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q3 2018 $2,101,431 $945,133 +$680,886 +258% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $1,420,545 $608,431 +$352,688 +138% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $1,067,857 $242,824 -$89,395 -27% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $1,157,252 $305,043 +$49,347 +19% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q3 2017 $1,107,905 $264,247 -$23,527 -8.2% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $1,131,432 $255,743 +$41,630 +19% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $1,089,802 $332,219 -$605,089 -65% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1
Q4 2016 $1,694,891 $255,696 +$182,177 +248% 01 Oct 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
Q3 2016 $1,512,714 $287,774 +$258,759 +892% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $1,253,955 $214,113 -$27,913 -12% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $1,281,868 $937,308 +$887,120 +1768% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $394,748 $73,519 01 Oct 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
Q3 2015 $29,015 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016 2016 Q3
Q2 2015 $242,026 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2
Q1 2015 $50,188 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1

Avalo Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,852,000 +$2,377,000 +68% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $3,475,000 -$4,079,000 -54% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $7,554,000 -$618,000 -7.6% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $8,172,000 +$1,386,000 +20% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $6,786,000 +$4,323,204 +176% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2022 2021 FY
2019 $2,462,796 +$31,733 +1.3% 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2021 2020 FY
2018 $2,431,063 +$1,273,811 +110% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
2017 $1,157,252 -$537,639 -32% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 $1,694,891 +$1,300,143 +329% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 $394,748 -$691,833 -64% 01 Jan 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
2014 $1,086,581 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.